Clinical trials
Autoimmune Diseases clinical trials
Below are recruiting autoimmune diseases clinical trials, each written for real people, not researchers. We’re tracking 252 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT06964269RecruitingPhase 4
Acthar Gel for dry eye and autoimmune disease
This trial tests a new injectable medicine, Acthar Gel, for moderate to severe dry eye and eye pain linked to autoimmune disease. It aims to see if the drug can relieve these symptoms safely.
Nashville, TennesseeAges 18–85 - NCT06983964Recruiting
CAR-T cell therapy for autoimmune diseases that haven't improved
This trial tests a personalized cell therapy (CAR-T) that targets a protein called CD19 on immune cells. It's for people with certain autoimmune diseases like lupus or scleroderma that are still active despite standard treatments. The goal is to see if this therapy can help control the disease when other options haven't worked.
Beijing, Beijing MunicipalityAges 18–65 - NCT06993493Recruiting
Car-T therapy for hard-to-treat autoimmune diseases
This trial tests whether a patient's own engineered immune cells (called CD19 CAR-T cells) can calm down overactive immune attacks in several autoimmune diseases like lupus, scleroderma, and myositis. It's for people whose disease isn't controlled by standard treatments.
Beijing, Beijing MunicipalityAges 18–65 - NCT07052565Recruiting
CAR-T cell therapy for autoimmune diseases
This trial uses your own engineered immune cells (CAR-T cells) to treat severe autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis that haven't improved with standard medicines. The goal is to see if this treatment can calm the immune system and reduce disease activity.
HefeiAges 18 years+ - NCT07059169Recruiting
CAR-T cell therapy for severe autoimmune diseases
This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.
Wuhan, HubeiAges 18 years+ - NCT07121777Recruiting
CAR T cell therapy for autoimmune diseases
This study tests a new type of cell therapy (CAR T cells) that targets certain immune cells to treat autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, and systemic sclerosis. It may help people whose disease is not well controlled with standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07122076RecruitingEarly Phase 1
GT719 injection for moderate to severe autoimmune diseases
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
ShanghaiAges 18–65 - NCT07193667Recruiting
CAR-T therapy for autoimmune diseases
This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.
Shenyang, LiaoningAges 18–65 - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT07283315RecruitingEarly Phase 1
NK cell therapy for children with autoimmune diseases
This trial tests a new treatment using special NK cells (a type of immune cell) designed to target and calm overactive B cells that cause autoimmune diseases like lupus and kidney inflammation. It may help children whose current treatments aren't working well enough.
Hangzhou, ZhejiangAges 3 years+ - NCT07305116RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
Hangzhou, ZhejiangAges 3 years+ - NCT03178630Recruiting
MRI scans to track outcomes in children with autoimmune liver disease
This study uses MRI scans to find “biomarkers,” or imaging clues, that may help predict how autoimmune liver conditions will progress in children and young adults. If you qualify, you may get MRI imaging to see whether it relates to future health outcomes.
Cincinnati, OhioAges 6–23 - NCT07408336RecruitingEarly Phase 1
Study of AFN50 injection for active lupus
This study tests an investigational injection called AFN50 for people whose lupus (SLE) remains active despite standard treatments. The goal is to see if the drug can safely help control lupus symptoms better than current therapies alone.
Hefei, AnhuiAges 18–69 - NCT07507201RecruitingEarly Phase 1
Car-T cells for autoimmune diseases like lupus
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
Hangzhou, ZhejiangAges 3 years+ - NCT07586267RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune blood diseases
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hangzhou, ZhejiangAges 3 years+ - NCT07275736RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
BeijingAges 18–75 - NCT05007340Recruiting
ILD and autoimmune conditions registry and sample storage
This study collects health information and may store blood or other samples to learn more about interstitial lung disease (ILD) and autoimmune-related conditions. Joining could help researchers understand different causes of ILD and improve future care.
Montreal, QuebecAges 18 years+ - NCT07095075RecruitingEarly Phase 1
LUCAR-DKS1 for severe autoimmune diseases
This early-phase trial tests an experimental treatment called LUCAR-DKS1, which uses your own immune cells to target and control severe autoimmune diseases like lupus, vasculitis, and scleroderma that haven't responded to other treatments.
Bengbu, AnhuiAges 18–70 - NCT07115745RecruitingPhase 1
Donor CAR T cells for severe autoimmune diseases
This study tests a new type of CAR T-cell therapy made from healthy donor cells. It is designed to help people with severe autoimmune diseases that have not improved with standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07448298RecruitingEarly Phase 1
Testing AFN50 for hard-to-treat autoimmune diseases
This study tests an experimental drug called AFN50 for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if AFN50 can help control the disease.
BeijingAges 18–69 - NCT01280825Recruiting
Testing how to use genetic medicine results in routine care
This study looks at how to put genetic testing results (pharmacogenomics) into regular doctor care. It aims to see whether using the results helps doctors choose safer, better-matched medications.
Chicago, IllinoisAges 18 years+ - NCT06900010RecruitingPhase 2
CM336 for Autoimmune Blistering Disease
This study tests a new drug called CM336 for people with autoimmune blistering diseases. The drug is designed to calm the immune system and reduce blistering, aiming to improve skin health.
JinanAges 18 years+ - NCT07252804RecruitingPhase 4
Testing the MenB vaccine safety and immune response in children with rheumatic disease
This trial tests a meningitis B vaccine (MenB-4C) in children and young adults with autoimmune rheumatic diseases. It aims to see if the vaccine is safe and works well for these patients.
São Paulo, São PauloAges 2–25
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmune diseases?
- Yes. Clin2 currently lists 252 recruiting autoimmune diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmune diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmune diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.